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GWAS to identify coronary artery disease risk variants 
Coronary artery disease (CAD) is one of the leading causes of mortality in the world and 
triggered by different risk factors, including diet, dyslipidaemia, diabetes, inflammation, and – 
importantly – also genetics1, 2. Indeed, heritable factors account for 40% to 60% of the risk to 
develop CAD1, and genome wide association studies (GWAS) have the potential to identify 
genetic variations associated with CAD. 
The first GWAS for CAD were published in 20073, which initiated an exciting era of 
cardiovascular systems genetics (also described as systems medicine) to detect new loci 
associated with cardiovascular complications4. Although several follow up studies led to the 
identification of various genetic polymorphisms that are associated with increased incidence of 
CAD or myocardial infarction (MI), including single nucleotide polymorphisms (SNPs), these 
identified variants only explain approximately 10% of the risk heritability4. 
One of the best ways to validate the cardiovascular function of genetic variants is to study their 
role in genetically modified model organisms5, 6. Importantly, a systematic review from von 
Scheidt et al. demonstrated that most CAD risk variants from GWAS display consistent 
phenotypes in experimental atherosclerosis mouse models7. 
 
JCAD – a new atherogenic player? 
Several GWAS studies have identified genetic variants at the junctional cadherin 5 associated 
(JCAD, also known as KIAA1462) locus to be associated with increased risk of CAD and MI, 
including rs3739998, rs2505083, and rs24879288-11. Recently, rs2487928 has been shown to 
reduce JCAD expression, which via the Hippo pathway has downstream consequences on a 
number of downstream phenotypes including angiogenesis12. In this issue of the European 
Heart Journal, Xu et al. (new REF) mechanistically examine this interesting question by 
characterizing Jcad knockout mouse models, performing vascular function studies, and 
assessing how JCAD modulation affects atherosclerosis development (Figure 1). 
 
Risk variants at the JCAD locus lead to increased JCAD expression  
The authors initially determined the magnitude and directionality of the association between 
JCAD risk variants and CAD by mining genotype data from GWAS and expression data from 
the Genotype-Tissue Expression (GTEx) database. They observed that the lead risk variants 
associate with increased JCAD expression levels (Figure 1A), that JCAD is highly expressed 
in endothelial-enriched organs, such as arteries, lungs and brain, and that the disease-
associated JCAD variants map to eQTLs most strongly in arterial tissues—particularly aorta. 
Given this association between CAD-risk variants and increased JCAD expression, the authors 
hypothesized that the deletion of Jcad would exert atheroprotective effects in mice. 
 
Systemic deletion of Jcad improves vascular function in mice 
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To test their hypothesis the authors first characterised whole-body Jcad knockout mice. When 
challenging the mice with a high-fat diet, Jcad knockouts displayed an improved endothelial-
dependent vascular relaxation compared to wildtype controls. Surprisingly, although JCAD is a 
structural membrane protein, vascular permeability was not affected in Jcad knockout mice. 
 
Systemic and endothelial cell-specific deletions of Jcad protect against atherogenesis 
in mice 
To further validate the contribution of JCAD to atherosclerosis, the authors crossbred whole-
body and endothelial cell-specific Jcad knockouts with atherosclerosis-susceptible Apoe-/- 
mice. Both mouse models with Jcad deficiency developed less atherosclerotic lesions 
compared to the control mice upon high-fat diet feeding. While there were no notable 
differences in blood lipid levels, smooth muscle cells, collagen content or inflammation, the 
authors demonstrate that macrophage staining is reduced in plaques. Consistently, VCAM-1 
expression and monocyte adhesion to mouse endothelial lung cells were reduced in Jcad 
knockout mice (Figure 1B). 
 
An atheroprotective JCAD-YAP-TAZ axis in endothelial cells 
Complementary RNA-sequencing studies in coronary artery endothelial cells showed that the 
expression of various pro-atherogenic genes was reduced, e.g. CTGF and CYR6113, 14, while 
the expression of atheroprotective genes was increased upon JCAD siRNA-mediated silencing. 
CTGF and CYR61 are transcriptional targets of the Hippo/YAP/TAZ pathway, further reinforcing 
this as the mechanistic pathway connecting JCAD to atherosclerosis. The authors performed 
further gain and loss-of-function experiments in endothelial cells (HUVECs) to demonstrate that 
JCAD interacts with several actin-binding proteins and activates the Hippo/YAP/TAZ pathway 
(Figure 1C), thus leading to the nuclear translocation and transcriptional activation of the 
complex, and consequently CTGF and CYR61 expression. 
 
Regulation and expression of JCAD in human endothelial cells and atherosclerotic 
plaques 
How is JCAD itself regulated? The authors tested different atherogenic, angiogenic and 
biochemical stimuli, and showed that the expression of JCAD is regulated by the blood flow, 
characterized by increased expression in areas with disturbed flow. Finally, the authors reveal 
that JCAD expression is increased in the aortic endothelium of mice upon high-fat diet feeding 
as well as in advanced human atherosclerotic plaques. 
 
Added value and open questions 
The current study of Xu et al. demonstrates that the deletion of Jcad is atheroprotective in mice 
and suggests that JCAD expression is increased in advanced human plaques. Together with 
the initial GWAS findings which indicate a causal relationship between JCAD and the incidence 
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of CAD in humans, this study highlights a potential new avenue for understanding and treating 
arterial diseases. Nevertheless, some questions remain open for future investigations, such as: 
Is the deletion of endothelial cell Jcad sufficient to improve vascular function in mice? This 
question could be easily addressed with the endothelial cell-specific knockout mouse model. 
How does blood flow regulate JCAD expression? As described by Jones et al., the RhoA 
signalling pathway might play a central role in this shear stress response12. Do the genetic 
variants that were identified in human GWAS lead to the same phenotype as the Jcad knockout 
mice? This last question could be addressed by using the CRISPR/Cas9 system to introduce 
the corresponding SNPs in an atherosclerotic mouse model and then assess atherosclerosis 
development. 
In a compound screening approach, the authors identified the BRD4 inhibitor JQ1 as a 
pharmacological inhibitor of JCAD expression. Notably, JQ1 protects against inflammation and 
atherosclerosis development15. It is therefore tempting to speculate that JQ1 may also confer 
atheroprotection by repressing the expression of JCAD, which would be of high 
pharmacological interest. 
 
Mechanistic understanding of GWAS hits 
GWAS have been established as a powerful tool for the de novo identification of genetic 
mechanisms affecting complex diseases, yet this approach has been beset by challenges 
related to the mechanistic understanding of resulting hits. The authors show here a strong 
example for validating GWAS targets by using a pipeline going from hypothesis discovery in 
human populations, to mechanistic examination in cell lines, then to genetically modified mice. 
As JCAD is shown to have a strong impact on atherosclerosis and likely other arterial-related 
diseases, the authors have established a clear path forward both for additional mechanistic 
understanding, and for clinical examinations in humans.  
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Figure 1. Scheme illustrating the CAD risk variants at the JCAD locus and the role of JCAD in 
experimental atherosclerosis. (A) Using a systems genetics approach Xu et al. demonstrate 
that the CAD risk variants at the JCAD locus lead to increased JCAD expression. (B) JCAD 
promotes the activation of the YAP/TAZ pathway and subsequent expression of pro-
inflammatory genes. Consequently, endothelial cells express higher levels of VCAM-1 and 
attract blood monocytes. (C) Jcad-deficient mice develop less atherosclerotic lesions that are 
characterized by a lower accumulation of macrophages and have an improved endothelial-
dependent vascular function. CAD, coronary artery disease; EC, endothelial cell; GTEx, 
Genotype-Tissue Expression database; GWAS, genome wide association study; HFD, high-fat 
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